Longbio Pharma

This early-stage study tested the safety and tolerability of a new drug called LP-005 in 68 healthy adults aged 18 to 50. The drug is being developed for paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. Participants received either a single or multiple doses to s…

This study tested a new medicine called LP-003 in 180 adults with moderate to severe seasonal allergies that standard treatments (like antihistamines and nasal sprays) don't fully control. LP-003 is a lab-made antibody that blocks IgE, a key driver of allergic reactions, and is d…

This study tested an experimental drug called LP-003 in 202 adults with chronic spontaneous urticaria (long-lasting hives and itching) that standard antihistamines couldn't fully control. Participants received injections of LP-003 or a placebo alongside their usual antihistamines…

This early-stage study tested a new drug called LP-003 in 60 healthy adults to see if it is safe and how the body processes it. The study had two parts: one group got a single dose, another got multiple doses. The goal was to check for side effects and measure drug levels in the …

This early-stage study tested a new drug called LP-001 in 68 healthy adults aged 18 to 50. The main goal was to see if it is safe and how the body processes it. No direct treatment was given; results will help plan future studies for people with myelodysplastic syndrome.